TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO, May 5,...
Hence then, the article about tremfya guselkumab positioned to become the first and only il 23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks )
Also on site :
- Wharton’s great contrarian says AI adoption isn’t an easy way to cut headcount: ‘The key thing … is just how much work is involved in doing it’
- Ex-husband charged in deaths of Monique and Spencer Tepe
- A Red State’s High Court Gave Sam Alito the Dobbs Rejoinder He Deserves